Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer have?
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer has 829 citations in the OpenAlex counts ScholarIQ stores.
When was Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer published?
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer has 2018 year in the ScholarIQ index.
What is the open-access status of Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer?
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer has gold oa status in the ScholarIQ index.
What is the DOI of Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer?
The DOI for Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer is on the source record.
What is the PMID of Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer?
The PMID for Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer is on the source record.
What is the OpenAlex record for Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer?
The OpenAlex for Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer is on the source record.